Search

Your search keyword '"Hungria, Vânia T M"' showing total 15 results
Start Over Author "Hungria, Vânia T M"
15 results on '"Hungria, Vânia T M"'

1. Efficacy and safety of single-agent belantamab mafodotin versus pomalidomide plus low-dose dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-3): a phase 3, open-label, randomised study

Author

Dimopoulos, Meletios Athanasios, Hungria, Vania T M, Radinoff, Atanas, Delimpasi, Sosana, Mikala, Gabor, Masszi, Tamas, Li, Jian, Capra, Marcelo, Maiolino, Angelo, Pappa, Vasiliki, Chraniuk, Dominik, Osipov, Iurii, Leleu, Xavier, Low, Michael, Matsumoto, Morio, Sule, Neal, Li, Mary, McKeown, Astrid, He, Wei, Bright, Shelley, Currie, Brooke, Perera, Sue, Boyle, Julia, Roy-Ghanta, Sumita, Opalinska, Joanna, and Weisel, Katja

Published
2023
Full Text
View/download PDF

2. Overall survival of patients with relapsed multiple myeloma treated with panobinostat or placebo plus bortezomib and dexamethasone (the PANORAMA 1 trial): a randomised, placebo-controlled, phase 3 trial

Author

San-Miguel, Jesús F, Hungria, Vania T M, Yoon, Sung-Soo, Beksac, Meral, Dimopoulos, Meletios A, Elghandour, Ashraf, Jedrzejczak, Wieslaw W, Günther, Andreas, Nakorn, Thanyaphong N, Siritanaratkul, Noppadol, Schlossman, Robert L, Hou, Jian, Moreau, Philippe, Lonial, Sagar, Lee, Jae H, Einsele, Hermann, Sopala, Monika, Bengoudifa, Bourras-Rezki, Binlich, Florence, and Richardson, Paul G

Published
2016
Full Text
View/download PDF

3. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial

Author

San-Miguel, Jesús F, Hungria, Vânia T M, Yoon, Sung-Soo, Beksac, Meral, Dimopoulos, Meletios Athanasios, Elghandour, Ashraf, Jedrzejczak, Wieslaw Wiktor, Günther, Andreas, Nakorn, Thanyaphong Na, Siritanaratkul, Noppadol, Corradini, Paolo, Chuncharunee, Suporn, Lee, Je-Jung, Schlossman, Robert L, Shelekhova, Tatiana, Yong, Kwee, Tan, Daryl, Numbenjapon, Tontanai, Cavenagh, Jamie D, Hou, Jian, LeBlanc, Richard, Nahi, Hareth, Qiu, Lugui, Salwender, Hans, Pulini, Stefano, Moreau, Philippe, Warzocha, Krzysztof, White, Darrell, Bladé, Joan, Chen, WenMing, de la Rubia, Javier, Gimsing, Peter, Lonial, Sagar, Kaufman, Jonathan L, Ocio, Enrique M, Veskovski, Ljupco, Sohn, Sang Kyun, Wang, Ming-Chung, Lee, Jae Hoon, Einsele, Hermann, Sopala, Monika, Corrado, Claudia, Bengoudifa, Bourras-Rezki, Binlich, Florence, and Richardson, Paul G

Published
2014
Full Text
View/download PDF

4. Whole-Body Imaging of Multiple Myeloma: Diagnostic Criteria

Author

Ormond Filho, Alípio G., primary, Carneiro, Bruno C., additional, Pastore, Daniel, additional, Silva, Igor P., additional, Yamashita, Sâmia R., additional, Consolo, Flávio D., additional, Hungria, Vânia T. M., additional, Sandes, Alex F., additional, Rizzatti, Edgar G., additional, and Nico, Marcelo A. C., additional

Published
2019
Full Text
View/download PDF

5. Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by prior treatment

Author

Richardson, Paul G., primary, Hungria, Vânia T. M., additional, Yoon, Sung-Soo, additional, Beksac, Meral, additional, Dimopoulos, Meletios Athanasios, additional, Elghandour, Ashraf, additional, Jedrzejczak, Wieslaw W., additional, Guenther, Andreas, additional, Nakorn, Thanyaphong Na, additional, Siritanaratkul, Noppadol, additional, Schlossman, Robert L., additional, Hou, Jian, additional, Moreau, Philippe, additional, Lonial, Sagar, additional, Lee, Jae Hoon, additional, Einsele, Hermann, additional, Sopala, Monika, additional, Bengoudifa, Bourras-Rezki, additional, Corrado, Claudia, additional, Binlich, Florence, additional, and San-Miguel, Jesús F., additional

Published
2016
Full Text
View/download PDF

6. Whole-Body Imaging of Multiple Myeloma: Diagnostic Criteria

Author

Filho, Alípio G. Ormond, Carneiro, Bruno C., Pastore, Daniel, Silva, Igor P., Yamashita, Sâmia R., Consolo, Flávio D., Hungria, Vânia T. M., Sandes, Alex F., Rizzatti, Edgar G., and Nico, Marcelo A. C.

Abstract

In the setting of multiple myeloma, newly available treatment options to extend patient survival and increasing recognition of biomarkers that can be used to identify patients at high risk of progression to active disease have led to revised diagnostic criteria.

Published
2019
Full Text
View/download PDF

7. Superiority of Triple Combination Bortezomib + Cyclophosphamide and Dexamethasone (VCD) Versus Thalidomide + Cyclophosphamide and Dexamethasone (CTD) in Newly Diagnosed Multiple Myeloma Transplant-Eligible Patients

Author

De Queiroz Crusoe, Edvan, Higashi, Fabiana, Martinez, Gracia, Bittencourt, Rosane, Maiolino, Angelo, Sousa, Lais, Nunes, Renata Ferreira Marques, Ribeiro, Glaciano, Nicacio, Jandir, Zanella, Karla Richter, Magalhaes, Andre, Leao, Danielle, Pinto Neto, Jorge Vaz, Hallack Neto, Abrahão Elias, Braga, Walter, Souza, Emmanuella G, Guimaraes, Antonio Julio A.M., Durigon, Giovanna Steffenello, Laks, Dani, Kutner, Jose Mauro, Colli, Gilberto, Santucci, Rodrigo, Magalhães, Roberto José Pessoa, and Hungria, Vania T M

Published
2017
Full Text
View/download PDF

8. Treatment Patterns and Survival Outcomes in Latin American Patients with Newly Diagnosed Multiple Myeloma: A Retrospective Medical Chart Review Study, 2008-2016

Author

Hungria, Vania T M, Martinez-Banos, Deborah M., Ramos Penafiel, Christian, Miguel, Carlos Eduardo, Vela-Ojeda, Jorge, Remaggi, Guillermina, Barroso Duarte, Fernando, Cao, Carmen, Silvana Cugliari, Maria, Santos, Telma, Santos, Eduardo, Machnicki, Gerardo, Lin, Jennifer Hsiang-Ling, Chen, Yen-Wen, and Barreyro, Paula

Published
2017
Full Text
View/download PDF

14. Panobinostat: a novel pan-deacetylase inhibitor for the treatment of relapsed or relapsed and refractory multiple myeloma.

Author

Richardson PG, Laubach JP, Lonial S, Moreau P, Yoon SS, Hungria VT, Dimopoulos MA, Beksac M, Alsina M, and San-Miguel JF

Subjects
Antineoplastic Combined Chemotherapy Protocols therapeutic use, Bortezomib administration & dosage, Clinical Trials as Topic, Dexamethasone administration & dosage, Disease-Free Survival, Histone Deacetylase Inhibitors adverse effects, Humans, Hydroxamic Acids administration & dosage, Hydroxamic Acids adverse effects, Hydroxamic Acids therapeutic use, Indoles administration & dosage, Indoles adverse effects, Indoles therapeutic use, Multiple Myeloma mortality, Multiple Myeloma pathology, Panobinostat, Histone Deacetylase Inhibitors therapeutic use, Hydroxamic Acids pharmacology, Indoles pharmacology, Multiple Myeloma drug therapy
Abstract

Outcomes for patients with multiple myeloma (MM) have improved significantly over the past decade. Despite these advances, MM remains incurable and an unmet medical need remains for patients who are relapsed and/or refractory. Panobinostat is a potent, oral pan-deacetylase inhibitor that elicits anti-myeloma activity through epigenetic modulation of gene expression and disruption of protein metabolism. Preclinical data demonstrated that panobinostat has synergistic effects on myeloma cells when combined with bortezomib and dexamethasone. In a Phase III clinical trial evaluating bortezomib and dexamethasone in combination with panobinostat or placebo in patients with relapsed or relapsed and refractory MM (PANORAMA 1), panobinostat led to a significant increase in median progression-free survival. Panobinostat is currently under regulatory review with a recent accelerated approval granted for the treatment of relapsed disease, in which both bortezomib and immunomodulatory drugs have failed. Here, we summarize the preclinical, pharmacokinetic and clinical data for panobinostat in MM.

Published
2015
Full Text
View/download PDF

15. Metabolism of chylomicron-like emulsions in patients with Hodgkin's and with non-Hodgkin's lymphoma.

Author

Gonçalves RP, Hungria VT, Chiattone CS, Pozzi DB, and Maranhão RC

Subjects
Adolescent, Adult, Aged, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Carbon Radioisotopes, Case-Control Studies, Cholesterol Esters blood, Cholesterol Esters metabolism, Chylomicrons blood, Emulsions administration & dosage, Emulsions metabolism, Female, Hodgkin Disease drug therapy, Humans, Kinetics, Lipolysis, Lymphoma, Non-Hodgkin drug therapy, Male, Middle Aged, Triglycerides blood, Triglycerides metabolism, Tritium, Chylomicrons metabolism, Hodgkin Disease metabolism, Lymphoma, Non-Hodgkin metabolism
Abstract

Background: Chylomicrons carry in the bloodstream dietary fats absorbed the intestine for storage in the body tissues such as adipose and muscle. The two-step chylomicron metabolism consists in lipolysis by lipoprotein lipase on vessel walls and hepatic uptake of triglyceride-depleted remnants. Chylomicron metabolism is understudied in cancer, despite its direct involvement in the patient nutritional status. We investigated this metabolism in Hodgkin and non-Hodgkin lymphoma patients, using the method of triglyceride-rich emulsions that mimic chylomicrons., Patients and Methods: The chylomicron-like emulsion, labeled with [9,10-3H]glycerol-trioleate and [1-14C] cholesteryl-oleate was intravenously injected into 11 Hodgkin's, 19 non-Hodgkin's patients and 12 healthy subjects. Triglyceride kinetics evaluate lipolysis whereas cholesteryl ester kinetics evaluate remnant removal., Results: Plasma total, LDL, HDL cholesterol, apo B, apo A1 and Lp(a) values were similar between the three groups, but VLDL cholesterol and triglycerides were higher in the lymphoma groups. The fractional catabolic rate (FCR, in min(-1)) of the emulsion triglycerides was roughly three-fold smaller in non-Hodgkin's (0.043+/-0.007, mean+/-S.E.M., P<0.001) and Hodgkin's (0.045+/-0.009, P<0.0001) lymphoma patients compared with the control values (0.151+/-0.032). FCR of the emulsion cholesteryl esters, was four-fold smaller in non-Hodgkin's (0.016+/-0.002, P<0.0001), and three-fold in Hodgkin's lymphoma patients (0.024+/-0.006, P<0.001) compared with the control group (0.069+/-0.013). The lipolysis index, calculated from the decay curves of both isotopes was also markedly smaller in both groups of lymphoma patients compared with the controls., Conclusions: In both lymphoma groups, marked alterations in chylomicron lipolysis and remnant removal occurs.

Published
2003
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results